Clinical trials: Secondary Resistance
Breast Cancer, Metastases
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic…
- Trial name
- NCT00080301
- Testing
- Ixabepilone + Capecitabine, Capecitabine
- Where
- 127 sites in United States, Argentina and 20 more
- Volunteers
- 752 people
- Sponsor
- R-Pharm
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253.
- Trial name
- NCT02987829
- Testing
- TRC253
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Castration-resistant Prostate Cancer
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effectiveness of Disitamab Vedotin in the treatment of subjects with locally advanced or metastatic castration-resistant prostate cancer.
- Trial name
- NCT06227156
- Testing
- Disitamab Vedotin Injection
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC)
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults…
- Conditions
- Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
- Trial name
- PSMA-013-001 (NCT07813637)
- Testing
- JANX013, JANX007
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Janux Therapeutics
Non-metastatic Castration-resistant Prostate Cancer
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
This is an observational cohort study in men with non-metastatic castration-resistant prostate cancer who received their usual treatment, which is 'Androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and…
- Trial name
- DEAR-EXT (NCT06013475)
- Testing
- Apalutamide, Darolutamide (BAY 1841788), Enzalutamide
- Where
- United States
- Volunteers
- 1,375 people
- Sponsor
- Bayer
Breast Cancer
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs.
- Trial name
- NCT00003253
- Testing
- paclitaxel, antitumor drug screening assay
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oncotech
HPV Associated Cancers
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers.
- Trial name
- NCT05826275
- Testing
- TGN-S11, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Toragen, Inc.
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Metastatic Castration Resistant Prostate Cancer
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
- Trial name
- NCT06517719
- Testing
- lutetium (177Lu) vipivotide tetraxetan
- Where
- 38 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer.
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
Prostate cancer that has returned after local treatment usually responds to hormone blocking treatment, but most patients eventually experience disease progression.
- Trial name
- NCT01734681
- Testing
- G-202
- Where
- United States
- Sponsor
- GenSpera, Inc.
Gastrointestinal Stromal Tumors (GIST)
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
The mainstay of therapy for GISTs is surgical resection, however, recurrence is almost inevitable in high-risk tumors and secondary surgery or other salvage therapy has yielded poor outcome.
- Trial name
- NCT00633295
- Testing
- AMN107- NILOTINIB
- Where
- 3 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
This is a phase 1b study in adult patients diagnosed with resistant or recurrent head and neck squamous cell carcinoma (HNSCC) designed to assess the safety and tolerability of IK-175 in combination with nivolumab.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer, Neck Cancer
- Trial name
- NCT05472506
- Testing
- IK-175 + nivolumab
- Where
- 4 sites in United States
- Sponsor
- Ikena Oncology
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC)
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate…
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
- Trial name
- NCT03460977
- Testing
- Mevrometostat (PF-06821497), Enzalutamide, Itraconazole
- Where
- 85 sites in United States, Bulgaria and 6 more
- Volunteers
- 453 people
- Sponsor
- Pfizer
Cancer of the Prostate, Neoplasms, Prostate
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
This study will be conducted in three parts. Part A is a dose-escalation study to determine two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate cancer.
- Conditions
- Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Cancer
- Trial name
- NCT02349139
- Testing
- ASN001: Escalating dose Part A
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Asana BioSciences
Epithelial Ovarian Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
- Trial name
- NCT00408603
- Testing
- Voreloxin Injection
- Where
- 20 sites in United States, Canada
- Volunteers
- 183 people
- Sponsor
- Sunesis Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- ProvONE (NCT06134232)
- Testing
- Sipuleucel-T Injection
- Where
- 31 sites in United States
- Volunteers
- 400 people
- Sponsor
- Dendreon
Breast Cancer
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial. Participants with advanced breast cancer (ABC) or Metastatic Breast Cancer (MBC) who have experienced recurrence or progression…
- Trial name
- NCT01437566
- Testing
- Fulvestrant, GDC-0941, GDC-0980
- Where
- 130 sites in United States, Argentina and 21 more
- Volunteers
- 318 people
- Sponsor
- Genentech, Inc.